Loading clinical trials...
Loading clinical trials...
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Conditions
Interventions
lanreotide (Autogel formulation)
Placebo
Locations
71
United States
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California, United States
University of Iowa
Iowa City, Iowa, United States
The John Hopkins Hospital
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Providence Portland Medical Center
Portland, Oregon, United States
Start Date
June 1, 2006
Primary Completion Date
April 1, 2013
Completion Date
April 1, 2013
Last Updated
March 5, 2025
NCT06228066
NCT05746208
NCT07129252
NCT05556473
NCT06889493
NCT06505824
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions